MedPath

Rosiglitazone

Generic Name
Rosiglitazone
Brand Names
Avandamet, Avandia
Drug Type
Small Molecule
Chemical Formula
C18H19N3O3S
CAS Number
122320-73-4
Unique Ingredient Identifier
05V02F2KDG

Overview

Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.

Background

Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.

Indication

Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions

  • Type 2 Diabetes Mellitus

Clinical Trials

FDA Approved Products

AVANDAMET
Manufacturer:Physicians Total Care, Inc.
Route:ORAL
Strength:2 mg in 1 1
Approved: 2012/08/30
NDC:54868-4965
AVANDAMET
Manufacturer:Physicians Total Care, Inc.
Route:ORAL
Strength:2 mg in 1 1
Approved: 2012/08/30
NDC:54868-5376
AVANDAMET
Manufacturer:Physicians Total Care, Inc.
Route:ORAL
Strength:4 mg in 1 1
Approved: 2012/08/30
NDC:54868-5157
AVANDAMET
Manufacturer:Physicians Total Care, Inc.
Route:ORAL
Strength:4 mg in 1 1
Approved: 2012/08/30
NDC:54868-5262

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath